Form 4: Eledon Pharmaceuticals President Acquires 840,438 Shares Through Option Vesting

Eledon Pharmaceuticals President, Steven Perrin, acquired 840,438 shares of common stock through the vesting of a stock option.

Summary

• Steven Perrin, President of Eledon Pharmaceuticals, acquired 840,438 shares of common stock.
• The acquisition occurred through the vesting of a stock option granted on May 1, 2023.
• The option's performance-based vesting criteria were met on November 21, 2024, for 840,438 shares.
• Time-based vesting criteria were met for 315,164 shares on November 1, 2024.
• The remaining 525,274 shares will vest in equal quarterly installments over three years, ending May 1, 2027.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation event. The vesting of shares is a positive sign that performance targets were met, but it is not an unusual event.

Positives

• The vesting of the stock options indicates that performance targets were met.
• The acquisition of shares by a key executive could be seen as a positive sign of confidence in the company's future.

Future Outlook

The remaining 525,274 shares of the stock option will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire shares. It reflects the company's compensation structure and performance-based incentives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry.
• Vesting schedules with both performance and time-based criteria are also standard practice.
• The specific vesting terms and amounts are specific to Eledon Pharmaceuticals and its executive compensation plan.

Stakeholder Impact

• Shareholders may view the vesting of shares as a positive sign of management's performance.
• The increase in shares held by the President may increase his alignment with shareholder interests.

Next Steps

• The remaining 525,274 shares will continue to vest quarterly until May 1, 2027.

Key Dates

Keywords

Eledon Pharmaceuticals, stock option, share acquisition, vesting, insider trading, Steven Perrin, executive compensation